SLU-PP-332: Exercise Mimetic Research Insights

What is SLU-PP-332 Peptide

SLU-PP-332 is a synthetic small molecule developed at Saint Louis University School of Medicine that acts as a selective estrogen related receptor alpha (ERRα) agonist. Unlike other peptides, SLU-PP-332 is orally available with high bioavailability and stability.

Molecular Structure and Chemical Data

SLU-PP-332, also known as 4-hydroxy-N’-(2-naphthylmethylene)benzohydrazide, has the CAS number 303760-60-3 and is a novel class of synthetic ERR agonists. This synthetic errα compound is a white to off-white crystalline solid with a density of 1.20 g/cm³.

For research use only, 99%+ purity is required and verified through NMR and HPLC testing. It’s soluble in DMSO up to 2mg/mL with a predicted pKa of 8.44. Storage should be at 2-8°C to maintain molecular integrity and prevent degradation.Handling protocols should be followed for proper storage and measurement. The compound is stable for extended research use when stored properly, making it suitable for long term metabolic studies and cellular research on mitochondrial biogenesis and energy metabolism pathways.

Research Areas for SLU-PP-332 Peptide

Mechanism Of Action For SLU-PP-332 Peptide

Future Research Directions For SLU-PP-332 Peptide

Buy SLU-PP-332 Peptide at Loti Labs

Quality control protocols ensure each batch meets high purity standards, with testing certificates documenting molecular integrity and 99%+ purity for reliable research results.

Standard packaging is 5-gram with 100mg measuring scoops for rodent models and cellular research. Storage guidelines are included with each shipment, refrigeration requirements and handling protocols to maintain compound stability during extended research periods.

Licensing requires institutional oversight and adherence to investigational use protocols for novel synthetic compounds. Customer support provides technical assistance for research applications to help investigators design experiments and comply with regulations for experimental therapeutics research.

Research must demonstrate legitimate scientific objectives and IRB approval for SLU-PP-332 studies. The compound is an investigational agent and requires documentation and adherence to protocols for handling experimental compounds in research settings.

Summary

Studies by Billon et al. (2023), Xu et al. (2023) and Wang et al.

The compound is investigational and more research is needed to establish therapeutic applications and long term safety in humans.

References

• Billon C, et al. (2023). ACS Chem Biol.* Xu L, et al. (2023). SLU-PP-332 in diet-induced obesity. J Metabolic Research.
• Wang K, et al. (2023). Cardiovascular Research.
• Saint Louis University School of Medicine. (2023). Design and synthesis of ERR modulators.